Advertisement

Maligne Lymphome

  • H. Fritsch
  • H. Kuttig

Zusammenfassung

Die Ätiologie der HL ist noch ungeklärt. Relevante Vorkrankheiten, die zum HL disponieren, sind bisher unbekannt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bagley C Jr, de Vita MT, Berard CW, Canellos GP (1972) Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with Cyclophosphamide, Vincristine and Prednisone. Ann Intern Med 76:227–234PubMedGoogle Scholar
  2. Bonadonna G, Uslenghi C, Zucali R (1975 a) Recent trends in the medical treatment of Hodgkin’s disease. Eur J Cancer 11:251PubMedCrossRefGoogle Scholar
  3. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975 b) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 36:252PubMedCrossRefGoogle Scholar
  4. Bonadonna G, Zucali R, De Lena M, Valagussa P (1977) Combined chemotherapy (MOPP or ABVD)- radiotherapy approach in advanced Hodgkin’s disease. Cancer Treat Rep 61:769PubMedGoogle Scholar
  5. Brucher H (1978) Chemotherapie der malignen Lymphome. Med Welt 29:1563PubMedGoogle Scholar
  6. Brunner KW, Maurice P, Sonntag RW (1973) CCNU (l-(2-Chloroethyl)-3-cyclohexyl-l-nitrosourea) und BCNU (l,3-Bis-(2-chloroethyl)-l-nitrosourea) sowie BCNU-Kombinationen beim Lymphogranuloma Hodgkin Stadium III und IV. In: Stacher A (Hrsg) Leukamien und maligne Lymphome. Urban &Schwarzenberg, München Berlin WienGoogle Scholar
  7. Brunner KW, Nagel GA (1976) (Hrsg) Internistische Krebstherapie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  8. Carbone PP, Kaplan HS, Musshoff K et al. (1971) Report of the comittee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861PubMedGoogle Scholar
  9. Chaffey JT, Rosenthal DS, Pinkus G, Hellmann A (1975) Advanced lymphosarcoma, treated by total body irradiation. Br J Cancer [Suppl] 11:441Google Scholar
  10. Cox JD, Koehl RH, Turner WM, King FM (1974) Irradiation in the local control of malignant lymphoreticular tumors (non-Hodgkin’s malignant lymphoma). Radiology 112:179PubMedGoogle Scholar
  11. De Vita VT, Serpick A, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881Google Scholar
  12. De Vita VT, Simon RM, Hubbard SM et al. (1980) Curability of advanced Hodgkin’s disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587Google Scholar
  13. Dorken H (1978) Zur Epidemiologic des Morbus Hodgkin. Klinikarzt 7:685Google Scholar
  14. Engelhardt R (1978) Maligne Lymphome. In: Fetzer J, Fullenbach D, Gabel H (Hrsg) Adriamycin Bd 2. Solide Tumoren und Hamoblastosen. Neue Moglichkeiten der Chemotherapie. Round-Ta- ble Gesprache Januar 1977 bis November 1977: Kehrer, FreiburgGoogle Scholar
  15. Fischer W, Folsch E (1975) Wandlungen der Diagnose und Therapie des Lymphosarcoms und Reticulosarcoms. Dtsch Med Wochenschr 100:630PubMedCrossRefGoogle Scholar
  16. Fischer J, Preiss J (1978) Staging maligner Lymphome. Klinikarzt 7:708Google Scholar
  17. Gallmeier WM, Bruntsch U (1981) Die Chemotherapie des Morbus Hodgkin. Internist 22:289PubMedGoogle Scholar
  18. Glatstein E, Donaldson SS, Rosenberg SA, Kaplan HS (1977) Combined modality therapy in malignant lymphomas. Cancer Treat Rep 61:1199Google Scholar
  19. Grace JT, Mittelmann A (1966) Surgery in the management of Hodgkin’s disease. Cancer 19:351–355CrossRefGoogle Scholar
  20. Gross R, Bredenbrocker H, Schmidt CG, Zach J (1981) Klinik und Prognostik des Morbus Hodgkin. Eine Studie anhand von 1200 eigenen Fallen. Internist 22:264PubMedGoogle Scholar
  21. Hartwich G (1978) Chemotherapie der malignen Lymphome. Klinikarzt 7:915Google Scholar
  22. Herman TS, Jones SE (1978) Systematic restaging in patients with Hodgkin’s disease: a southwest oncology group study. Cancer 42:1976PubMedCrossRefGoogle Scholar
  23. Horton J (1977) The lymphomas. In: Horton J, Hill GJ (eds) Clinical oncology. Saunders, PhiladelphiaGoogle Scholar
  24. Jackson H, Parker F (1947) Hodgkin’s disease and allied disorders. Oxford University Press, New YorkGoogle Scholar
  25. Jones SE, Fuks Z, Bull M et al. (1973) Non-Hodgkin’s lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer 31:806PubMedCrossRefGoogle Scholar
  26. Kaiserling E (1978) Klassifikation der malignen Lymphome. Klinikarzt 7:689Google Scholar
  27. Lauria F, Baccarani M, Fiacchini MG, Tura S (1975) Methotrexate, cyclophosphamide and vincristine (MEV-regimen) for non Hodgkin’s lymphomas. Eur J Cancer 11:343PubMedCrossRefGoogle Scholar
  28. Lennert K (1978) Malignant lymphomas other than Hodgkin’s disease. Springer, Berlin Heidelberg New York (Handbuch der speziellen pathologischen Anatomie und Histologic, Bd 1/3B)CrossRefGoogle Scholar
  29. Luce JK, Frei E III, Gehan EA, Coltman CHA Jr, Talley R, Monto RW (1973) Chemotherapy of Hodgkin’s disease. Arch Intern Med 131:391PubMedCrossRefGoogle Scholar
  30. Lukes RJ, Craver LL, Hall TC, Rappaport H, Rubin P (1966 a) Hodgkin’s disease, report of Nomenclature Committee. Cancer Res 26:1311Google Scholar
  31. Lukes RJ, Butler JJ, Hicks EB (1966 b) Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer 10:317–344CrossRefGoogle Scholar
  32. McKelvey EM, Gottlieb J A, Wilson HE et al. (1976) Hydroxyldannomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484PubMedCrossRefGoogle Scholar
  33. Moxley JH III, de Vita T, Brace K, Frei E III (1967) Intensive combination chemotherapy and x-irradiation in Hodgkin’s disease. Cancer Res 27:1258PubMedGoogle Scholar
  34. Musshoff K (1972) Grundlagen der Strahlentherapie des Morbus Hodgkin. Indikation und Ergebnisse. Z Krebsforsch 78:162CrossRefGoogle Scholar
  35. Musshoff K (1978) Die Strahlentherapie der malignen Lymphome. Klinikarzt 7:894Google Scholar
  36. Musshoff K, Boutis L (1969) Die Behandlungsergebnisse der malignen Lymphogranulomatose (Morbus Hodgkin) in Abhangigkeit von individuellen und krankheitsspezifischen Faktoren und der Therapie. Klin Wochenschr 47:93–101PubMedCrossRefGoogle Scholar
  37. Musshoff K, Slamina J (1974) Die Strahlenbehandlung der Lymphogranulomatose. Internist 15:85PubMedGoogle Scholar
  38. Musshoff K, Schmidt-Vollmer H (1975) Prognosis of non-Hodgkin’s lymphomas with special emphasis on the staging classification. Z Krebsforsch 83:323CrossRefGoogle Scholar
  39. Osieka R, Bruntsch U, Gallmeier WM, Seeber S, Schmidt CG (1976) Post-MOPP-chemotherapie des M. Hodgkin. Dtsch Med Wochenschr 101:1177PubMedCrossRefGoogle Scholar
  40. Rappaport H (1966) Tumors of the hematopoietic system. Armed Forces Institute of Pathology, Washington (Atlas of tumor pathology III/8) Rosenberg SA (1966) Report of the committee on the staging of Hodgkin’s disease. Cancer Res 26:1310Google Scholar
  41. Rosenberg SA, Kaplan HS, Brown BW (1979) The role of adjuvant MOPP in the therapy of Hodgkin’s disease: an analysis after ten years. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer II. Grune&Stratton, New YorkGoogle Scholar
  42. Santoro A, Bonadonna G, Bonfante V, Valagussa P (1980) Non cross resistant regimes (MOPP and ABVD) VS MOPP alone in stage IV Hodgkin’s disease (HD). Proc Am Soc Clin Oncol 21:470Google Scholar
  43. Stein RS, Golomb HM, Ultmann JE, Wiernik PH, Diggs C, Hellman S, Mauch P (1979) Anatomic substages of stage III Hodgkin’s disease (HD): a collaborative study. Proc Am Soc Clin Oncol 20:438Google Scholar
  44. Swan HT, Knowelden J (1971) Prognosis in Hodgkin’s disease related to Lymphocyte Count. Br J Haematol 21:343–349PubMedCrossRefGoogle Scholar
  45. Ziegler JL, Magrath IT, Deisseroth AB et al. (1978) Combined modality treatment of Burkitt’s lymphoma. Cancer Treat Rep 62:2031PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • H. Fritsch
  • H. Kuttig

There are no affiliations available

Personalised recommendations